Clinical review report: Doravirine (Pifeltro) (Merck Canada Inc.) indication: Doravirine (Pifeltro) is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to Doravirine

The objective of this systematic review was to evaluate the beneficial and harmful effects of doravirine, in combination with other antiretroviral medicinal products, for the treatment of HIV-1 infection in adults without past or present evidence of viral resistance to Doravirine

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH June 2019, 2019
Edition:	Final (with redactions)
Series:	CADTH common drug review
Subjects:	Anti-retroviral Agents / Therapeutic Use Anti-retroviral Agents / Adverse Effects Canada Reverse Transcriptase Inhibitors / Therapeutic Use Reverse Transcriptase Inhibitors / Adverse Effects Drug Therapy, Combination Hiv Infections / Drug Therapy Treatment Outcome
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK544868
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa